Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.54 |
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | HPGD | P15428 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | TP53 | P04637 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.54 |
| ▸ | S100A4 | P26447 | 1/20 | 0.54 |
| ▸ | MTOR | P42345 | 1/20 | 0.54 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28938489 | 1.00 | ALDH1A1 (0.54) | ALDH1A1TDP1MAPTHPGDMEN1 | |
| SCHEMBL29634902 | 0.79 | ALDH1A1 (0.60) | ALDH1A1TDP1MAPTHPGDMEN1 | |
| SCHEMBL20774482 | 0.79 | ALDH1A1 (0.60) | ALDH1A1TDP1MAPTHPGDMEN1 | |
| SCHEMBL20774483 | 0.79 | ALDH1A1 (0.60) | ALDH1A1TDP1MAPTHPGDMEN1 | |
| SCHEMBL11834947 | 0.79 | ALDH1A1 (0.55) | ALDH1A1TDP1MAPTHPGDMEN1 | |
| SCHEMBL11834941 | 0.79 | ALDH1A1 (0.55) | ALDH1A1TDP1MAPTHPGDMEN1 | |
| SCHEMBL10589798 | 0.76 | HPGD (0.55) | ALDH1A1TDP1MAPTHPGDMEN1 | |
| SCHEMBL10954580 | 0.76 | ALDH1A1 (0.38) | ALDH1A1TDP1TP53KDM4ETSHR | |
| SCHEMBL11835667 | 0.73 | PTGES2 (0.48) | ALDH1A1TDP1MAPTHPGDMEN1 | |
| SCHEMBL742012 | 0.73 | ALDH1A1 (0.67) | ALDH1A1TDP1MAPTHPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011130395-A1 | INHIBITORS OF FLIP TO TREAT CANCER | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2011-10-20 | — | — | WO | disclosed |
| US-20110251135-A1 | INHIBITORS OF PERITONEAL SEEDING OF CANCER CELLS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2011-10-13 | — | — | US | disclosed |
| US-7989495-B2 | 3-Sulfonyl propenenitriles, e.g., BAY 11-7085 (3-(t-butylphenylsulfonyl)-2-propenenitrile; promoting apoptosis and inhibiting readhesion of cancer cells; antimetastasis agents, particularly for hepatic, parietal or peritoneal area; inhibiting tumorigenesis; antiproliferative agents (not for myeloma) | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2011-08-02 | — | — | US | disclosed |
| EP-2281077-A2 | INHIBITORS OF PERITONEAL SEEDING OF CANCER CELLS | University of Utah Research Foundation (US) | 2011-02-09 | — | — | EP | disclosed |
| WO-2009124272-A2 | INHIBITORS OF PERITONEAL SEEDING OF CANCER CELLS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2009-10-08 | — | — | WO | disclosed |
| US-20050124590-A1 | Compositions and methods for inhibiting nf-kappab mediated tumorigenicity and adhesion dependent survival of cancer cells | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-06-09 | — | — | US | disclosed |
| WO-2003072038-A2 | COMPOSITIONS AND METHODS FOR INHIBITING NF-κB MEDIATED TUMORIGENICITY AND ADHESION-DEPENDENT SURVIVAL OF CANCER CELLS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2003-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124590-A1 | Compositions and methods for inhibiting nf-kappab mediated tumorigenicity and adhesion dependent survival of cancer cells | NFKBIA, RELA, NFKB1 | ALDH1A1 1727/4885TDP1 2499/4885MAPT 4444/4885 |
| US-20110251135-A1 | INHIBITORS OF PERITONEAL SEEDING OF CANCER CELLS | NFKBIA, IKBKB, RELA | ALDH1A1 2392/4885TDP1 3746/4885MAPT 3675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.